ADMS News and Press, Adamas Pharmaceuticals Inc. From 02/01/21

- GOCOVRI is now the first and only medication approved to treat OFF and dyskinesia motor complications - - Adamas to host webcast conference call today at 4:30 pm ET/1:30 pm PT - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and deli...

After a gain of ~6.4% today, the shares of Adamas Pharmaceuticals (ADMS) was halted for trading with news pending.The news underlying the trading halt has not been specified, however, today is the FDA action date for the company’s marketing application for Gocovri (amantadine) to treat...

Adamas Pharmaceuticals (ADMS) inks settlement agreement with Zydus Pharmaceuticals resolving its ongoing litigation concerning Zydus’s Abbreviated New Drug Application ((ANDA)) seeking FDA approval to market a generic version of Gocovri (amantadine) extended-release capsules. Under the...

- Adamas grants Zydus license for generic version of GOCOVRI ® as of March 4, 2030 - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurol...

Adamas has become much less exciting the last few years with sales of GOCOVRI slowing in its second year. They decided to give up on attempting to treat the walking speed in those with Multiple Sclerosis with GOCOVRI after lackluster results. Hope remains with a new CEO, Neil McFa...

Gainers: [[ADMS]] +13.2%. [[CTMX]] +5.6%. [[MSTR]] +4.9%. [[FARM]] +4.8%. [[NERV]] +4%.Losers: [[CATB]] -10.6%. [[PTVE]] -8%. [[MRVI]] -3.9%. [[ZI]] -3.8%. [[ICON]] -3.5%. For further details see: MSTR, ZI, ADMS and CATB among after-hours movers

Gainers: [[BBBY]] +17.7%. [[IMMP]] +15.8%. [[FHTX]] +7.6%. [[TLSA]] +6.8%. [[ADMS]] +6.8%.Losers: [[TTOO]] -20.3%. [[VIR]] -17.0%. [[GRTX]] -16.6%. [[AGIO]] -8.4%. [[WMG]] -7.7%. For further details see: BBBY, IMMP, TTOO and VIR among after-hours movers

Adamas Pharmaceuticals (ADMS) expects total revenue for Q4 to be $20.8M and $74.2M for FY 2020.Product sales of GOCOVRI is expected to be $19.8M for Q4, an increase of 21% from same quarter prior year and $71.2M for FY 2020.“I am proud of our team’s resilience, ab...

-- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI ® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 -- -- Total prescriptio...

EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executiv...